The psoriasis drugs market was valued at USD 13,418 million in 2020, and it is expected to reach USD 23,628 million in 2026, registering a CAGR of 9.89% during the forecast period, 2021-2026.
Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients. Global Data projects the Psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies.
Psoriasis is a chronic, autoimmune, relapsing, inflammatory disease triggered by deregulated thymus-derived cells (T cells), resulting in inflammation and benign hyperplasia of keratinocytes within the skin affecting around 2-3% of the world’s population. Manifestations of affected skin are red thickened plaques with an overlying silver-white scale, which significantly impairs the patient’s physical and mental wellbeing.The Asia-Pacific (APAC) psoriasis market is forecast to grow from $933.1m in 2017 to $1,997.3m in 2024, at a compound annual growth rate (CAGR) of 11.5%.